18.04.2024 - 46.2% of patients demonstrated a 1- or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in the AXPAXLI arm, compared to 0% in the control arm No patients in the AXPAXLI group experienced worsening in DRSS compared to . Seite 1
Ocular Therapeutix (OCUL) Reports Positive Topline Phase 1 Data for AXPAXLI streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Each month, our editorial staff compiles a recap of the top news in ophthalmology. Our March 2024 ophthalmology month in review features a recap of the latest news from the ophthalmic pipeline.
A single ABBV-RGX-314 gene therapy treatment has the potential to become a new standard-of-care option among anti-VEGF treatments by sustaining vision health.
Regenxbio (RGNX) Announces Lancet Publication of Phase I/IIa Study of ABBV-RGX-314 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.